Marshall Wace North America’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Marshall Wace North America’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$10.3M	Buy	+511,674	New	+$14.1M	0.04%	347
2021 Q1	–	Sell	-17,903	Closed	-$394K	–	1891
2020 Q4	$394K	Sell	17,903 -73,907	-80%	-$1.63M	﹤0.01%	1130
2020 Q3	$1.65M	Buy	+91,810	New	+$1.9M	0.01%	648
2020 Q2	–	Sell	-115,666	Closed	-$2.13M	–	1597
2020 Q1	$2.13M	Sell	115,666 -96,123	-45%	-$1.87M	0.02%	468
2019 Q4	$4.67M	Buy	211,789 +211,274	+41,024%	+$4.25M	0.02%	403
2019 Q3	$8K	Buy	+515	New	+$7.36K	﹤0.01%	1268
2019 Q2	–	Sell	-17,886	Closed	-$261K	–	1786
2019 Q1	$261K	Buy	17,886 +12,939	+262%	+$149K	﹤0.01%	924
2018 Q4	$53K	Buy	+4,947	New	+$65.1K	﹤0.01%	1241

Other funds holding DRNA

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Marshall Wace North America's DRNA Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021: 511,674 shares worth $10.3M. The stake represents 0.04% of the portfolio and ranks #347 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in DRNA as recently as Q4 2020.

Marshall Wace North America first reported a position in DRNA in Q4 2018 and has held it in 8 quarters since. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Marshall Wace North America held 511,674 shares of Dicerna Pharmaceuticals, Inc. worth $10.3M as of Q3 2021.
Dicerna Pharmaceuticals, Inc. was a new Marshall Wace North America position in Q3 2021.
Dicerna Pharmaceuticals, Inc. made up 0.04% of Marshall Wace North America's portfolio in Q3 2021, its #347 holding.
Marshall Wace North America first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2018 and has held it in 8 quarters since.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.